Journal articles
Majidi A; Na R; Jordan SJ; Ross TL; DeFazio A; Friedlander M; Grant P; Webb PM, 2026, 'Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) study', Cancer Epidemiology, 100, http://dx.doi.org/10.1016/j.canep.2025.102961
Lee CK; Kartikasari AER; Bound NT; Francis KE; Shield-Artin K; Bedo J; Nesic K; Diamante K; O’Connell RL; Madondo M; Cox M; Davies C; Deceneux C; Goodchild G; Jarratt A; Cassar E; Amer H; Kariyawasam UGIU; Lee YC; Lombard J; Baron-Hay S; Antill Y; Shannon C; Selva-Nayagam S; Beale P; Zebic D; Simon S; Linaker A; Quinn MA; Papenfuss AT; Wakefield MJ; Vandenberg CJ; Friedlander M; Scott CL; Plebanski M, 2025, 'Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-64130-6
Petousis S; Kahramanoglu I; Appenzeller-Herzog C; Angeles MA; Margioula-Siarkou C; Kacperczyk-Bartnik J; Bilir E; Chatzakis C; Caruso G; Bizzarri N; Dinas K; Bowtell DDL; Garsed DW; Ray-Coquard I; Ledermann JA; Friedlander M; Sotiriadis A; Heinzelmann-Schwarz V; Zwimpfer TA, 2025, 'PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis', JAMA Network Open, 8, pp. e2541648, http://dx.doi.org/10.1001/jamanetworkopen.2025.41648
Garsed D; Zwimpfer T; Fereday S; Pandey A; Ariyaratne D; Jayawardana M; Twomey L; Laumont C; Kennedy C; Bolithon A; Meagher N; Milne K; Hamilton P; Alsop J; Antoniou A; Au-Yeung G; Beckmann M; de Gonzalez AB; Bisinotto C; Blome F; Bodelon C; Boros J; Brand A; Carney M; Cazorla-Jimenez A; Chiu D; Christie E; Chudecka-Glaz A; Coulson P; Cushing-Haugen K; Cybulski C; Darcy K; David C; Davidson T; Ekici A; Elishaev E; Emons J; Engler T; Farrell R; Fischer A; Garcia-Closas M; Gentry-Maharaj A; Ghatage P; Glasspool R; Harter P; Hartkopf A; Hartmann A; Heikaus S; Hernandez B; Hettiaratchi A; Heublein S; Huntsman D; Jimenez-Linan M; Jones M; Kang E; Kaznowska E; Kluz T; Kommoss F; Konecny GE; Kruitwagen R; Kwon J; Lambrechts D; Lee C-H; Lester J; Leung S; Leung Y; Linder A; Lissowska J; Loverix L; Lubiński J; Mateoiu C; McNeish I; Moubarak M; Nelson G; Nevins N; Olawaiye A; Olbrecht S; Orsulic S; Osorio A; Quinn C; Mohan GR; Ray-Coquard I; Rodriguez-Antona C; Roxburgh P; Rübner M; Salfinger S; Samra S; Schoemaker M; Sinn H-P; Sonke G; Steele L; Stewart C; Talhouk A; Tan A; Tarney C; Taylor S; de Vijver KV; der Aa MA; Gorp TV; Nieuwenhuysen EV; van Wagensveld L; Wahner-Hendrickson A; Walter C; Wang C; Welz J; Wentzensen N; Wilkens L; Winham S; Winterhoff B; Anglesio M; Berchuck A; do Reis FC; Cohen P; Conrads T; Crowe P; Doherty J; Fasching P; Fortner R; Garcia M; Gayther S; Goodman M; Gronwald J; Harris H; Heitz F; Horlings H; Karlan B; Kelemen L; Maxwell G; Menon U; Modugno F; Neuhausen S; Schildkraut J; Staebler A; Sundfeldt K; Swedlow A; Vergote I; Wu A; Brenton J; Pharoah P; Pearce C; Pike M; Goode E; Ramus S; Köbel M; Nelson B; DeFazio A; Friedlander M; Bowtell D, 2025, 'Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.', Res Sq, http://dx.doi.org/10.21203/rs.3.rs-7572112/v1
Ngoi NYL; Choi CH; Zhu J; Lim D; Tan TZ; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Lim SE; Goss G; Goh JC; Kim JW; Friedlander M; Tai BC; Kim K; Tan DSP, 2025, 'Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial', Clinical Cancer Research, 31, pp. 3907 - 3915, http://dx.doi.org/10.1158/1078-0432.CCR-25-0201
Konstantinopoulos PA; Kim JW; Freyer G; Lee JY; Gaba L; Grisham RN; Colombo N; Wu X; Sehouli J; Cruz F; Cibula D; Monk BJ; Nyvang GB; Friedlander M; Lorusso D; Van Nieuwenhuysen E; Malik R; Glasspool R; Marth C; Leary A; Cortés-Salgado A; Zamagni C; Marmé F; Sufliarsky J; Hinson P; Zuradelli M; Wang C; Su F; Paule I; Miller M; Matulonis UA; González-Martín A, 2025, 'Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation', Journal of Clinical Oncology, 43, pp. 2908 - 2917, http://dx.doi.org/10.1200/JCO-25-00225
Renz M; Friedlander M; Berek JS, 2025, 'Cancer of the ovary, fallopian tube, and peritoneum: 2025 update', International Journal of Gynecology and Obstetrics, 171, pp. 6 - 35, http://dx.doi.org/10.1002/ijgo.70282
Gersekowski K; Defazio A; Friedlander M; Obermair A; Webb PM, 2025, 'Green tea consumption, primary treatment outcome and survival after a diagnosis of ovarian cancer', Journal of Epidemiology and Community Health, 79, pp. 684 - 690, http://dx.doi.org/10.1136/jech-2024-222687
Francis KE; Lord SJ; Simon S; Friedlander M; Gebski V; Simes J; Lee CK, 2025, 'Under the radar - Frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf230
Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Leath CA; Cella D; Sun Z; Patel S; Tang Z; Ratajczak CK; Aghajanian C; Bookman MA, 2025, 'Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results', European Journal of Cancer, 225, http://dx.doi.org/10.1016/j.ejca.2025.115587
Friedlander ML; Anderson L; Lee YC, 2025, 'Erratum to ‘Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101668] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001938), (10.1016/j.ijgc.2025.101668))', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101953
Marth C; Moore RG; Bidziński M; Pignata S; Ayhan A; Rubio MJ; Beiner M; Hall M; Vulsteke C; Braicu EI; Sonoda K; Wu X; Frentzas S; Mattar A; Lheureux S; Chen X; Hasegawa K; Magallanes-Maciel M; Choi CH; Shalkova M; Kaen D; Wang PH; Berger R; Okpara CE; McKenzie J; Yao L; Orlowski R; Khemka V; Gilbert L; Makker V; Gomez Abuin G; Zamora LB; Alfie MS; Casarini IA; Harrison M; Ananda S; Shannon CM; Friedlander M; Meniawy T; Gao B; Baron-Hay S; Diakos C; Polterauer S; Petru E; De Bock M; Baurain JF; Van Gorp T; Altintas S; Lima JPDSN; De Freitas Junior R; Santana RO; De Melo AC; Franke FA; Zibetti Dal Molin G; Damian FB; Guedes JDC; Ellard S; Tinker A; Samouëlian V; Fortin S; Bessette P; Kolinsky M; Kumar Tyagi N; Ethier JL; MacKay H; Lim C; Pan L; An R; Zheng H; Wu Y; Zhu J; Yao S; Jia X; Huang Y; Lv W; Zhang Y; Zhou Q; Ma C; Chekerov R; Mach P; Witteler R; Marmè F; Cadoo K; Korach J; Levy T; Amnon A; Scollo P; Naglieri E; Zamagni C; Salutari V; Usami T; Nakamura K; Matsumoto K; Yamagami W; Kobayashi Y; Takano M; Kato H; Kikuchi A; Katsumata N, 2025, 'First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 43, pp. 1083 - 1100, http://dx.doi.org/10.1200/JCO-24-01326
Friedlander ML; Anderson L; Lee YC, 2025, 'Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101668
Phillips KA; Kotsopoulos J; Domchek SM; Terry MB; Chamberlain JA; Bassett JK; Aeilts AM; Andrulis IL; Buys SS; Cui W; Daly MB; Eisen AF; Foulkes WD; Friedlander ML; Gronwald J; Hopper JL; John EM; Karlan BY; Kim RH; Kurian AW; Lubinski J; Metcalfe K; Nathanson KL; Singer CF; Southey MC; Symecko H; Tung N; Narod SA; Milne RL; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Bodek S; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Chenevix-Trench G; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; Defazio A; Delatycki M; Dickson R; Dixon J; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Gaff C; Gattas M; George P; Greening S; Harris M; Hart S; Harraka P; Hayward N; Hopper J; Hoskins C; Hunt C; James P; Jenkins M; Kidd A; Kirk J; Koehler J; Kollias J; Lakhani S; Lawrence M; Lee J; Li S; Lindeman G; Lippey J; Lipton L; Lobb L; Loi S; Mann G, 2025, 'Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2', Journal of Clinical Oncology, 43, pp. 422 - 431, http://dx.doi.org/10.1200/JCO.24.00176
Lee YC; Whitely A; Burling M; Anderson L; Cohen PA; Naidoo M; Richardson G; Perera S; Scott CL; Friedlander M; Brand A; McNally O; Hyde S; Bunting M; Jobling T; Zalcberg J; Rome R, 2025, 'Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2024.100052
Na R; Jordan SJ; DeFazio A; Williams M; Livingstone K; Obermair A; Friedlander M; Grant P; Webb PM, 2025, 'Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival—A prospective cohort study in Australia', International Journal of Cancer, 156, pp. 280 - 292, http://dx.doi.org/10.1002/ijc.35154
Francis KE; Simon S; Gebski V; Joly F; Ledermann JA; Penson RT; Oza AM; Korach J; Lainez N; Cecere SC; Tasca G; Gropp-Meier M; Fujiwara K; Lowe ES; Friedlander M; Pujade-Lauraine E; Lee CK, 2025, 'Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer', Gynecologic Oncology, 192, pp. 50 - 55, http://dx.doi.org/10.1016/j.ygyno.2024.11.004
Pitiyarachchi O; Friedlander M, 2025, 'Age disparities in clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with high grade serous ovarian cancer: A wake up call to improving outcomes in older patients', Journal of Geriatric Oncology, 16, http://dx.doi.org/10.1016/j.jgo.2024.102152
Na R; Nagle CM; Bartsch S; Ibiebele TI; Williams M; Grant P; Friedlander ML; Webb PM, 2025, 'Use of Dietary Supplements Before, During and After Treatment for Ovarian Cancer: Results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study', Nutrition and Cancer, 77, pp. 200 - 209, http://dx.doi.org/10.1080/01635581.2024.2408775
Campbell R; Jeon M; Friedlander M; King MT; Obermair A; Bilic S; Brand A; Butow P; Codde J; Gebski V; Goh JC; Ives A; Lawson W; McNally O; Meniawy T; Mileshkin LR; Morton RL; Webb PM; Yates P; Cohen PA, 2025, '“The telehealth means I get distance from the hospital so I don’t feel so much like a patient”: A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations.', Journal of Clinical Oncology, 43, pp. 12099 - 12099, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.12099
Haggstrom L; Lee YC; Ginesta MPB; Jaeger A; Kaiser S; Woopen H; Rhind M; Frenel J-S; Hussain A; Bischof K; Mongillo M; Brodsky AL; Ledermann JA; Ghezelayagh T; Boere IA; Alonso CM; Rosengarten OS; Tucker KM; Friedlander ML, 2025, '1077P How long is long enough? An international GCIG collaboration investigating long term outcomes of exceptional responders with platinum sensitive recurrent ovarian cancer treated with PARP inhibitors', Annals of Oncology, 36, pp. S722 - S723, http://dx.doi.org/10.1016/j.annonc.2025.08.1715
Nicum S; Ledermann JA; Friedlander ML; Mileshkin L; Lee YC; King MT; Mercieca-Bebber R; Smith J; Wilkinson K; Counsell N, 2025, '1089P Telling it as it is: Quality of life outcomes associated with maintenance olaparib and cediranib following a response to chemotherapy in relapsed platinum-sensitive ovarian cancer', Annals of Oncology, 36, pp. S728 - S729, http://dx.doi.org/10.1016/j.annonc.2025.08.1727
Pitiyarachchi O; Sim H-W; OConnell R; Lanceley A; Lobbedez FJ; Hilpert F; Sehouli J; Pignata S; Berton-Rigaud D; Kaminsky-Forrett M-C; Okamoto A; Yoshida Y; Donnellan P; Oza AM; Lindemann K; Berek JS; Ledermann JA; Friedlander ML, 2025, '1131P Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG+)', Annals of Oncology, 36, pp. S752 - S752, http://dx.doi.org/10.1016/j.annonc.2025.08.1767
Cohen PA; Obermair A; Gebski V; King MT; Butow P; Campbell R; Bilic S; Brand A; Codde J; Goh JCH; Ives A; Kiberu AD; Lawson W; Mellon A; McNally O; Meniawy T; Mileshkin L; Morton R; Webb P; Friedlander ML, 2025, 'CN88 A phase II randomized trial of nurse led telehealth follow-up including patient reported outcomes using the MOST-S26 (measure of ovarian symptoms and treatment concerns) versus routine clinic based or telehealth follow-up, after completion of chemotherapy in patients with ovarian cancer', Annals of Oncology, 36, pp. S1650 - S1650, http://dx.doi.org/10.1016/j.annonc.2025.08.1166
Petousis S; Kahramanoglu I; Appenzeller-Herzog C; Kacperczyk-Bartnik J; Angeles MA; Bilir E; Caruso G; Friedlander M; Margioula-Siarkou C; Sotiriadis A; Heinzelmann-Schwarz V; Zwimpfer TA, 2025, 'Efficacy And Safety Of PARP Inhibitor Maintenance In Platinum-Sensitive Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review And Meta-Analysis', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 35, http://dx.doi.org/10.1016/j.ijgc.2024.100336
Nahm SH; Kiely BE; O'Connell RL; Lee YC; Davis A; Avall-Lundqvist E; Berek JS; Berton D; Donnellan P; Hilpert F; Joly F; Lanceley A; Ledermann JA; Okamoto A; Oza A; Pignata S; Sehouli J; King MT; Friedlander M; Stockler MR; Roncolato FT; GCIG Symptom Benefit Group , 2025, 'Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.', Int J Gynecol Cancer, 35, pp. 100030, http://dx.doi.org/10.1016/j.ijgc.2024.100030
Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Barnes EH; Goldstein D; Park SB, 2025, 'Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathy', Clinical Neurophysiology, 176, pp. 2110921 - 2110921, http://dx.doi.org/10.1016/j.clinph.2025.2110921
Haggstrom L; Lee YC; Scott C; Harter P; Woelber L; Ledermann J; Gourley C; McNeish IA; Amant F; Ray-Coquard I; Leary A; Oza AM; Tinker A; González Martin A; Cecere SC; Pignata S; Colombo N; Yoshida H; Marth C; Rosengarten O; Moore KN; Gómez-García EM; Tan D; Friedlander ML, 2024, 'How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes', International Journal of Gynecological Cancer, 34, pp. 1932 - 1939, http://dx.doi.org/10.1136/ijgc-2024-005976
Ramachandran D; Tyrer JP; Kommoss S; DeFazio A; Riggan MJ; Webb PM; Fasching PA; Lambrechts D; García MJ; Rodríguez-Antona C; Goodman MT; Modugno F; Moysich KB; Karlan BY; Lester J; Kjaer SK; Jensen A; Høgdall E; Goode EL; Cliby WA; Kumar A; Wang C; Cunningham JM; Winham SJ; Monteiro AN; Schildkraut JM; Cramer DW; Terry KL; Titus L; Bjorge L; Thomsen LCV; Pejovic T; Høgdall CK; McNeish IA; May T; Huntsman DG; Pfisterer J; Canzler U; Park-Simon TW; Schröder W; Belau A; Hanker L; Harter P; Sehouli J; Kimmig R; de Gregorio N; Schmalfeldt B; Baumann K; Hilpert F; Burges A; Winterhoff B; Schürmann P; Speith LM; Hillemanns P; Berchuck A; Johnatty SE; Ramus SJ; Chenevix-Trench G; Pharoah PDP; Dörk T; Heitz F; Bowtell D; Fereday S; Traficante N; Hung J; Friedlander M; Obermair A; Grant P; Beesley V; Blomfield P; Brand A; Davis A; Leung Y; Nicklin J; Quinn M; Livingstone K; O’Neill H; Williams M, 2024, 'Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease', Npj Genomic Medicine, 9, http://dx.doi.org/10.1038/s41525-024-00395-y
Tjokrowidjaja A; Kok PS; Antill YC; Scott CL; Mileshkin LR; Friedlander ML; Lee CK, 2024, 'Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas—a meta-analysis', Jnci Cancer Spectrum, 8, http://dx.doi.org/10.1093/jncics/pkae101
Lefkovits YR; Heriot N; Sporik A; Perera S; Friedlander M; Dixon C; Cohen PA; Lee YC; Hyde S; Richardson G; Webb P; Rome R; King M; Zalcberg J; Schofield P, 2024, 'Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges', BMC Health Services Research, 24, http://dx.doi.org/10.1186/s12913-024-11042-8
Burdett NL; Willis MO; Pandey A; Twomey L; Alaei S; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; Malt M; Chiew YE; Stenlake A; Sullivan H; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; White J; Jayde V; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Ball C; Young C; Brooks J; Mileshkin L; Au-Yeung G; Phillips K; Rischin D; Delahunty R; Christie E; Garsed D; Fox S; Johnson D; Lade S; Loughrey M; O’Callaghan N; Murray W; Purdie D; Whiteman D; Proietto A; Braye S; Otton G; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Beale P; Beith J; Carter J; Dalrymple C; Houghton R; Russell P; Davy M; Oehler MK; Hall C; Dodd T; Blomfield P, 2024, 'Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-50137-y
Ross TL; Na R; Au-Yeung G; DeFazio A; Friedlander M; Sivakumaran T; Livingstone K; Nagle CM; O'Neill H; Williams M; Webb PM; Beesley VL, 2024, 'Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?', Gynecologic Oncology, 190, pp. 53 - 61, http://dx.doi.org/10.1016/j.ygyno.2024.07.684
Ray-Coquard I; Casali PG; Croce S; Fennessy FM; Fischerova D; Jones R; Sanfilippo R; Zapardiel I; Amant F; Blay JY; Martin-Broto J; Casado A; Chiang S; Dei Tos AP; Haas R; Hensley ML; Hohenberger P; Kim JW; Kim SI; Meydanli MM; Pautier P; Abdul Razak AR; Sehouli J; Van Houdt W; Planchamp F; Friedlander M, 2024, 'ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas', International Journal of Gynecological Cancer, 34, pp. 1499 - 1521, http://dx.doi.org/10.1136/ijgc-2024-005823
Zwimpfer TA; Ewald H; Bilir E; Jayawardana M; Appenzeller-Herzog C; Bizzarri N; Razumova Z; Kacperczyk-Bartnik J; Heinzelmann-Schwarz V; Friedlander M; Bowtell DDL; Garsed DW, 2024, 'Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma', Cochrane Database of Systematic Reviews, 2024, http://dx.doi.org/10.1002/14651858.CD015896
McDonald JA; Liao Y; Knight JA; John EM; Kurian AW; Daly M; Buys SS; Huang Y; Frost CJ; Andrulis IL; Colonna SV; Friedlander ML; Hopper JL; Chung WK; Genkinger JM; Macinnis RJ; Terry MB, 2024, 'Pregnancy-Related Factors and Breast Cancer Risk for Women Across a Range of Familial Risk', JAMA Network Open, 7, pp. e2427441, http://dx.doi.org/10.1001/jamanetworkopen.2024.27441
Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy', JAMA Network Open, 7, pp. e2424139, http://dx.doi.org/10.1001/jamanetworkopen.2024.24139
Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M, 2024, 'Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over', Gynecologic Oncology, 187, pp. 221 - 226, http://dx.doi.org/10.1016/j.ygyno.2024.05.021
Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M, 2024, 'Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer', Gynecologic Oncology, 185, pp. 128 - 137, http://dx.doi.org/10.1016/j.ygyno.2024.02.025
Li T; Timmins HC; Mahfouz FM; Mizrahi D; Horvath L; Harrison ML; Grimison PS; Friedlander M; Marx GM; Boyle FM; Wyld D; Henderson R; King T; Baron-Hay SE; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Identifying optimized assessment of nerve damage during chemotherapy.', Journal of Clinical Oncology, 42, pp. 12016 - 12016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12016
Naidoo M; Scott CL; McNally O; Rome R; Perera S; Lee YC; Whitely A; Burling M; Anderson L; Cohen P; Richardson GE; Friedlander M; Brand A; Hyde S; Bunting M; Jobling T; Zalcberg JR, 2024, 'Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).', Journal of Clinical Oncology, 42, pp. e17554 - e17554, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e17554
Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE, 2024, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial', Translational Oncology, 43, http://dx.doi.org/10.1016/j.tranon.2024.101914
Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.', Support Care Cancer, 32, pp. 292, http://dx.doi.org/10.1007/s00520-024-08460-z
Ganz PA; Bandos H; Španić T; Friedman S; Müller V; Kuemmel S; Delaloge S; Brain E; Toi M; Yamauchi H; De Dueñas EM; Armstrong A; Im SA; Song CG; Zheng H; Sarosiek T; Sharma P; Geng C; Fu P; Rhiem K; Frauchiger-Heuer H; Wimberger P; T'Kint De Roodenbeke D; Liao N; Goodwin A; Chakiba-Brugère C; Friedlander M; Lee KS; Giacchetti S; Takano T; Henao-Carrasco F; Virani S; Valdes-Albini F; Domchek SM; Bane C; McCarron EC; Mita M; Rossi G; Rastogi P; Fielding A; Gelber RD; Scheepers ED; Cameron D; Garber J; Geyer CE; Tutt ANJ, 2024, 'Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer', Journal of Clinical Oncology, 42, pp. 1288 - 1300, http://dx.doi.org/10.1200/JCO.23.01214
Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK; Khoon Lee C; You B; Paoletti X; Glasspool R; Friedlander M; Scott C; Mirza M; Antill Y; Mileshkin L; Ethier JL; Bookman M; Gourley C, 2024, 'Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor', Journal of Clinical Oncology, 42, pp. 1301 - 1310, http://dx.doi.org/10.1200/JCO.23.01182
Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG, 2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690
Diéras V; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Loirat D; Ratajczak C; Adamu H; Girardi V; Arun BK, 2024, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial', European Journal of Cancer, 200, http://dx.doi.org/10.1016/j.ejca.2024.113580
Zebic DS; Tjokrowidjaja A; Francis KE; Friedlander M; Gebski V; Lortholary A; Joly F; Hasenburg A; Mirza M; Denison U; Cecere SC; Ferrero A; Pujade-Lauraine E; Lee CK, 2024, 'Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer', British Journal of Cancer, 130, pp. 425 - 433, http://dx.doi.org/10.1038/s41416-023-02528-z
Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK, 2024, 'Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00296
Kumari S; Moujaber T; Gloss B; Madsen I; Gao B; Provan P; Srirangan S; Bouantoun N; Kennedy C; Traficante N; Friedlander ML; Brand A; Gourley C; Garsed DW; Bowtell D; Harnett P; Balleine R; Defazio A, 2024, '8P Biomarkers to predict chemotherapy response in low-grade serous ovarian carcinoma', ESMO Open, 9, pp. 103508 - 103508, http://dx.doi.org/10.1016/j.esmoop.2024.103508
Back to profile page
https://orcid.org/0000-0003-3090-795X